BMO Capital Starts Merck (MRK) at Market Perform

New Data Show Dramatic Emotional Toll of Pandemic on Unpaid Caregivers of People Living With Cancer, Affecting Mental Health and Relationships

One in 5 (21%) cancer caregivers report negative impact of being a caregiver during the pandemic on relationship with the person they care for Lack of support cited as one of biggest challenges cancer caregivers face, and 94% say more mental health/wellness resources are needed

ROCKLAND, Mass.--(BUSINESS WIRE)-- More than two-thirds (69%) of unpaid caregivers of people living with cancer in the United States say the pandemic has worsened their emotional and mental health, and a similar percentage (66%) say the pandemic has made caregiving harder overall. These... More

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery

KEYTRUDA Is Now Approved for the Adjuvant Treatment of Patients With RCC at Intermediate-High or High Risk of Recurrence Following Nephrectomy, or Following Nephrectomy and Resection of Metastatic Lesions

KEYTRUDA Is the First Immunotherapy Approved for the Adjuvant Treatment of These Patients With RCC

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Mercks anti-PD-1 therapy, for the adjuvant treatment of patients with... More

Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck’s Inadequate Offer

Believes Transaction Comes at the Wrong Time, With the Wrong Price, and Following the Wrong Process

Remains Confident in Companys Standalone Opportunities Given Strong Momentum and Near-Term Inflection Point Coming from Phase 3 Data

Stands Ready to Help an Independent Acceleron Succeed

NEW YORK--(BUSINESS WIRE)-- Avoro Capital Advisors (Avoro), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed funds (Avoro, we or us) beneficially owns approximately 7% of Acceleron Pharma Inc. (Nasdaq: XLRN) (Acceleron, XLRN or... More

Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma Inc.

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in connection with Mercks pending acquisition of Acceleron Pharma Inc. (Nasdaq: XLRN) expired at 11:59 p.m., Eastern Time, on Nov. 16, 2021.

As previously announced on Oct. 12, 2021, Merck commenced, through a subsidiary, Astros Merger Sub, Inc., a cash tender offer to purchase all outstanding shares of common stock of Acceleron, for $180 in cash,... More

Merck and Ridgeback to Present Phase 3 Data for Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, at American Society of Tropical Medicine and Hygiene (ASTMH) 2021 Annual Meeting

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that new Phase 3 data for molnupiravir, an investigational oral COVID-19 antiviral medicine, will be presented as a late-breaking poster (#LB-5319) at the American Society of Tropical Medicine and Hygiene (ASTMH) 2021 Annual Meeting taking place virtually from Nov. 17-21. Poster data will be available on Wednesday, Nov. 17 at 9 a.m. ET and presented during Poster Session C from 11 a.m.-12:30 p.m. ET on Saturday, Nov. 20.

Imugene Announces Clinical Trial Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate HER-Vaxx in Combination with Avelumab for Treatment of Gastric Cancer

New clinical trial supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc.Avelumab (BAVENCIO®) to be provided to Imugene for Phase 2 clinical study in HER-2 positive gastric or gastroesophageal junction adenocarcinomas (neoHERIZON)neoHERIZON will assess HER-Vaxx in combination with chemotherapy with or without avelumab in HER-2 positive gastric cancer

SYDNEY, Australia., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Imugene (ASX: IMU) today announced a new clinical trial supply agreement with Merck KGaA, Darmstadt, Germany (ETR:... More